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Abstract | Systemic sclerosis (SSc) is a complex autoimmune disease of unclear aetiology. A multitude of 
genetic studies, ranging from candidate-gene studies to genome-wide association studies, have identified a 
large number of genetic susceptibility factors for SSc and its clinical phenotypes, but the contribution of these 
factors to disease susceptibility is only modest. However, in an endeavour to explore how the environment 
might affect genetic susceptibility, epigenetic research into SSc is rapidly expanding. Orchestrated by 
environmental factors, epigenetic modifications can drive genetically predisposed individuals to develop 
autoimmunity, and are thought to represent the crossroads between the environment and genetics in SSc. 
Therefore, in addition to providing a comprehensive description of the current understanding of genetic 
susceptibility underlying SSc, this Review describes the involvement of epigenetic phenomena, including DNA 
methylation patterns, histone modifications and microRNAs, in SSc.
Broen, J. C. A. et al. Nat. Rev. Rheumatol. advance online publication 19 August 2014; doi:10.1038/nrrheum.2014.128
Introduction
The aetiology of systemic sclerosis (SSc) is poorly under­
stood. The main manifestations of this severe auto­
immune disease are vasculopathy, immune activation and 
extensive fibrosis of the skin and internal organs.1 Two 
subsets of patients with SSc exist on the basis of the extent 
of skin fibrosis: limited cutaneous SSc (lcSSc) and diffuse 
cutaneous SSc (dcSSc). This classification also partially 
reflects the severity of the disease and the association 
with specific autoantibodies: lcSSc is more commonly 
associated with isolated pulmonary hypertension, late 
smouldering progression of the disease, and the presence 
of anti­centromere autoantibodies (ACA); dcSSc is more 
prominently linked to the development of interstitial lung 
disease and musculoskeletal manifestations with early, 
dramatic onset, and the presence of anti­topoisomerase 
autoantibodies (ATA).2 In addition, the presence of anti­
RNA polymerase III autoantibodies has been linked to 
susceptibility to renal crisis in patients with SSc.3
Intense research into SSc over the past 10 years has 
resulted in many genetic and environmental factors 
being implicated in disease susceptibility, and SSc has 
also been linked to the development of cancer.4–6 In less 
than a decade, genetic analysis techniques have advanced 
from small cohorts of candidate­gene studies to complex 
genome­wide analyses in large multinational cohorts, 
expediting the discovery of various genetic factors that 
contribute to SSc susceptibility. Findings from these 
studies have given us novel insights into the pathways 
and cell types that are likely to be involved in SSc patho­
genesis, but these data still face further investigation 
through functional research and for clinical relevance.
We aim, in this Review, to provide an extensive over­
view of these genetic risk factors, and to be critical of what 
this knowledge has revealed in terms of dis ease patho­
genesis. Given that the pathogenesis of SSc cannot be 
attributed solely to genetic causes and the fact that, of all 
autoimmune diseases, this disease has the lowest concor­
dance rate among monozygotic twins, research over the 
past 5 years has shifted focus to epigenetics. Multiple 
environmental factors have been suggested to be involved 
in SSc susceptibility—occupational exposure to silica 
(silicon dioxide) is most often reported6—inducing epi­
genetic modifications that can promote the development 
of autoimmunity in genetically predisposed individuals. 
A discussion of such epigenetic modifications is the focus 
of the latter part of this article.
The role of genetics in SSc
Family and twin studies
As with many rheumatic and autoimmune diseases, 
SSc is not inherited in a Mendelian fashion; however, 
the disease can occur in families in which a member has 
already been diagnosed with SSc or another autoim­
mune disease. Having a sibling with SSc is one of the 
highest risk factors for developing SSc (a 15–19­fold 
increase over the general population) and other first­
degree relatives have a 13–15­fold increased risk of 
developing SSc compared with the general population. 
Although this finding seems to be a sharp increase in 
risk rates, the absolute risk of developing SSc is only 1.6% 
in these relatives, compared with 0.026% in the general 
population.7–10 These findings were strengthened by a 
study of the Utah Population Database, a genealogical 
resource that contains data on the family structure and 
medical records of more than 7 million inhabitants of 
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Utah, USA.11 Analysis of 1,037 unique patients with SSc 
from this database revealed that 50 families affected by 
SSc had significant elevated familial standardized inci­
dence ratios (2.07–17.60) and that an increased relative 
risk existed for other autoimmune disease in the first and 
second­degree relatives.
A study in 2003 of 42 twin pairs (24 monozygotic 
and 18 dizygotic), of which at least one sibling had SSc, 
revealed that only two pairs—both female–female, one 
monozygotic and one dizygotic pair—were concord­
ant for SSc. No statistically significant difference in the 
concordance rates between monozygotic twins (4.2%) 
and dizygotic twins (5.6%) was observed.12 However, a 
number of the twins in the study were below the peak­
of­onset age for SSc; therefore, some of the healthy twins 
might be prone to develop SSc in later life.
Candidate-gene studies
Multiple candidate­gene studies of SSc have been 
carried out. Most often, the candidate genes and single­ 
nucleotide polymorphisms (SNPs; Box 1) were selected 
on the basis of their involvement in the susceptibility 
to other autoimmune diseases; a comprehensive list of 
associated non­HLA SNPs is provided in Supplemen­
tary Table 1 online. These SNPs, and multiple HLA 
associ ations, are discussed extensively elsewhere.4,13 
Here, we will try to consider the findings within a larger 
Key points
 ■ Systemic sclerosis (SSc) is a complex autoimmune disease, the pathogenesis  
of which is influenced by genetic, epigenetic and environmental factors
 ■ Candidate-gene studies and genome-wide association studies have identified a 
large number of genetic susceptibility factors for SSc and its clinical phenotypes
 ■ The low concordance rate for monozygotic twins demonstrates that a genetic 
basis cannot account exclusively for SSc pathogenesis and that epigenetic 
factors influenced by the environment are important
 ■ Several DNA methylation patterns, histone modifications and microRNAs (miRNAs) 
are altered in different cell types from patients with SSc; altered circulating 
miRNAs are potentially useful as disease diagnostic and prognostic biomarkers
framework by showing that the candidate genes reside in 
overlapping pathways that function separate to antigen 
presentation, as suggested by HLA associations.
T-cell signalling
The most frequently described SNP involved in SSc 
susceptibility is located in the gene encoding signal 
transducer and activator of transcription 4 (STAT4).14–18 
STAT4 is required for the development of type 1 T helper 
(TH1) cells from naive CD4+ cells and mediates the pro­
duction of IFN­γ, processes that are strongly impli­
cated in SSc pathogenesis.19 Consistent with a role for 
STAT4 in SSc, in a mouse model of bleomycin­induced 
skin fibrosis, deletion of Stat4 resulted in impaired T­cell 
activation and reduced fibrosis.18
SNPs in TNFSF4, which encodes TNF ligand super­
family member 4 (also known as OX40 ligand [OX40L]) 
have also been found to exacerbate the risk of develop­
ing SSc. These polymorphisms highlight the involve­
ment of T­cell signalling in SSc susceptibility, as 
TNFSF4 is the natural ligand of TNF receptor super­
family member 4, which is expressed on the surface of 
T cells and influences T­cell survival and proliferation.20 
How ever, in contrast to the aforementioned STAT4 sus­
ceptibility regions, TNFSF4 variants were found to be 
associated with disease phenotype rather than overall 
SSc susceptibility.21,22
As mice lacking Tbx21, which encodes the TH1­cell 
transcription factor T­bet, develop extensive fibrosis 
after injection with bleomycin, researchers investigated 
a potential role for this gene in SSc as well.22–24 A study 
of white American patients and healthy individuals 
controls found that a variant of TBX21 was involved in 
SSc susceptibility, regardless of the clinical phenotype. 
Interestingly, homozygous carriers of the rs11650354 
TT variant had higher expression of TH2 cytokines than 
people with the CC genotype, and the CC genotype was 
associated with a type I interferon signature.16
On the basis that T cells can dampen the inflam­
masome by inhibiting nucleotide­binding oligo­
meriza tion domain, leucine­rich repeat and pyrin 
domain­ containing protein 1 (NLRP1) responses, and 
that NLRP1 variants conferred susceptibility to auto­
immune disorders,25 a potential role for this gene in SSc 
was investigated. In a study comprising an identification 
cohort of 870 patients with SSc and 962 healthy con­
trols and a replication set consisting of 1,060 patients 
with SSc and 625 healthy controls, a variant of NLRP1 
was found to confer susceptibility to ATA­positive SSc 
phenotypes and fibrosing alveolitis.25,26
B-cell signalling
Associations between defects in B­cell signalling com­
ponents and SSc pathogenesis have also been described, 
highlighting a role for the immune system, rather than 
intrinsic fibroblast defects, in disease susceptibility. Two 
polymorphisms—rs13277113 and rs2736340—within 
the FAM167A­BLK region are known to be associated 
with lcSSc and dcSSc. The FAM167A­BLK region has 
been investigated in multiple autoimmune diseases;27 
Box 1 | SNPs and GWAS
 ■ SNPs are changes in single base pairs that influence gene function differently 
depending on where they occur in a gene. Whereas their presence in an exon 
could cause an amino-acid substitution or premature termination, SNPs that 
occur within a splice region could promote alternative splicing and those 
occurring within a promoter or in the 3' untranslated region could influence 
gene expression. Furthermore, on the basis of linkage disequilibrium, SNPs 
can also be used to indicate the presence of certain genomic regions in 
close proximity to their own locus. Consequently, the SNP itself might not be 
responsible for conferring disease susceptibility but might be physically linked 
to a genomic region that contains a real causative variant. So, whereas some 
candidate-gene studies use variants that confer altered protein function, 
others will be based on linkage disequilibrium.
 ■ GWAS take advantage of the fact that SNPs provide information about their 
surrounding genomic region. Screening large numbers of SNPs enables 
differences within the whole genome between cases and controls to be 
identified. The precision of a genome-wide scan depends heavily on the number 
of markers used, and this approach is not always able to detect rare genomic 
variants. The next step in genomic analyses will, therefore, be full-genome 
sequencing, which covers all nucleotides in the genome.
Abbreviations: GWAS, genome-wide association studies; SNP, single-nucleotide polymorphisms.
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BLK is a kinase that is expressed in thymocytes and is 
involved in signalling downstream of the B­cell recep­
tor.29,30 Both variants also seem to be more prevalent 
in ACA­positive lcSSc.22 The association between 
rs13277113 and SSc was replicated in a study of Japanese 
patients.28 When stratifying patients based on their geno­
type, RNA expression profiling revealed a difference in 
activation of BCR­related pathways between genotypes.31
A second B­cell­specific candidate gene encodes 
B­cell scaffold protein with ankyrin repeats (BANK1), 
an adaptor protein involved in signalling downstream 
of the B­cell antigen receptor. Research into BANK1 
polymorphisms in SSc has mostly been based on find­
ings from studies of patients with systemic lupus erythe­
matosus (SLE) or rheumatoid arthritis (RA).32,33A large 
multicentre study of 2,380 white patients with SSc and 
3,270 ethnically matched healthy controls revealed a sig­
nificant association of rs10516487 and rs17266594 with 
dcSSc. An independent replication study confirmed 
these results.34,35
Also of particular interest are two studies that impli­
cate the IRAK1 gene in the development of pulmonary 
fibrosis in SSc.36,37 As IRAK1 is located on the X chromo­
some, these findings might have a role in the high preva­
lence of SSc in women. The exact contribution, however, 
needs to be further investigated by X­chromosomal gene 
expression and in vitro experiments. 
Taken together, the candidate­gene studies show that 
polymorphisms tend to cluster in pathways involved in 
B­cell and T­cell receptor signalling and development. 
These findings lead to the hypothesis that SSc is a dis­
ease originating from the defective interaction of B cells 
and T cells.
Genome-wide association studies
Genome­wide association studies (GWAS) have expe­
dited the discovery of multiple novel polymorphisms 
that increase susceptibility to SSc or to one of its clinical 
phenotypes. Definitions for SNPs and GWAS are given 
in Box 1.
GWAS and SSc susceptibility
The first SSc GWAS, carried out in 137 Korean patients 
with SSc and 564 healthy controls, analysed 500,568 SNP 
markers and discovered associations of SNPs within the 
HLA­DPB1 region with SSc susceptibility, ATA posi­
tivity and ACA positivity.38 In 2010, the largest GWAS 
to date—involving 2,296 patients with SSc and 5,171 
healthy controls—not only confirmed a strong associ­
ation with HLA and replicated the association of SSc 
with the genes encoding interferon regulatory factor 
(IRF) 5 and STAT4 (Supplementary Table 1 online), 
but also identified five non­HLA loci, of which CD247 
reached genome­wide significance after replication;39 
the CD247 association has been robustly replicated in 
a white French population.40 CD247 encodes the T­cell 
receptor ζ subunit, a component of the T­cell receptor 
complex, and the results, therefore, underscore the rel­
evance of the antigen­presenting cell–T­cell interaction 
in the pathogenesis of SSc.
GWAS and SSc phenotype
A GWAS was conducted in a French cohort consisting 
of 564 SSc cases and 1,776 healthy controls followed by 
replication in 1,682 SSc cases and 3,926 healthy con­
trols. Psoriasis susceptibility 1 candidate gene 1 protein 
(PSORS1C1), TNF alpha­induced protein 3 (TNFAIP3)­
interacting protein 1 (TNIP1) and ras homolog gene 
family member B (RHOB) loci were identified as novel 
gene regions associated with SSc susceptibility.41 Further­
more, the involvement of STAT4, IRF5 and CD247 was 
confirmed.41 A large follow­up study corroborated the 
association of TNIP1, but did not find any association 
with PSORS1C1 or RHOB.42 Data from a follow­up of 
the French GWAS suggested that PPARG, which encodes 
peroxisome proliferator­activated receptor­γ, was asso­
ciated with SSc, although genome­wide significance 
was not reached.43 Another follow­up study found that 
IL12RB2, which encodes the β2 subunit of the IL­12 
receptor that is functionally linked to STAT4, CD247 
and IFN­γ, was associated with SSc.44
A genome­wide meta­analysis of SLE and SSc in a 
cohort with a sample size of 21,109 (6,835 cases and 
14,274 controls) identified KIAA0319L as a novel suscep­
tibility locus for SSc and SLE, and found the previously 
described SLE susceptibility loci PXK and JAZF1 to be 
shared with SSc.45 Intriguingly, the researchers found that 
KIAA0319L was overexpressed by the peripheral blood 
cells of patients with SSc or SLE compared with healthy 
controls. However, the role of KIAA0319L has not yet 
been fully elucidated.
Finally, an Immunochip study with high­resolution 
coverage of immune­associated loci of 1,833 systemic 
sclerosis (SSc) cases and 3,466 healthy controls identi­
fied DNASE1L3 (involved in DNA degradation in apop­
tosis), SCHIP1-IL12A (encodes a component of the 
IFN­γ pathway), ATG5 (involved in IFN­α signalling 
and autophagy), and TREH-DDX6 (has a role in RNA 
degradation and microRNA [miRNA]­induced gene 
silencing) as susceptibility loci for SSc; the data were later 
validated using a replication cohort comprising 4,017 SSc 
cases and 5,935 controls.46
Several follow­up GWAS have focused on identify­
ing the genetic components that contribute to clinical 
pheno type rather than SSc susceptibility. So far, these 
efforts have led to the discovery that IRF8 is specifi­
cally associated with lcSSc. The same study also dem­
onstrated that HLA­DQB1 is associated with ACA 
positivity, whereas HLA­DPA1/B1 was associated with 
ATA positivity. Less discriminating was NOTCH4, 
which was associated with the presence of both ACA 
and ATA.47 Altogether, GWAS show that T­cell signal­
ling and interferon signalling pathways are involved in 
SSc susceptibility, and reveal roles in apoptosis, DNA or 
RNA degradation and autophagy.45,46
Exploring the field of epigenetics
The aforementioned studies show that genetic factors are 
unable to fully account for the risk of SSc de velopment—
particularly when considering the extremely low con­
cordance rates of SSc in monozygotic twins (4.2%).12 
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These findings suggest that the environment can affect 
the breakage of immune tolerance and the development 
of fibrosis and SSc in certain genetic backgrounds. This 
concept is supported by numerous studies indicating that 
different environmental factors, including occupational 
exposure to silica dust, vinyl chloride or drugs such as 
bleomycin, can induce SSc­like symptoms48 (Figure 1). 
Interestingly, no clear association between smoking and 
the risk of developing SSc has been established.49
The individual role of environmental factors in SSc 
risk is difficult to evaluate, owing to the rarity and 
hetero geneity of the disease.50 The overall effect of 
single agents is, however, estimated to be modest, con­
sidering the size of the ‘exposed’ population compared 
with the low prevalence of SSc. Accordingly, it is thought 
that multiple factors, each of them having a mild effect, 
can contribute to the development of SSc in individu­
als with a genetic predisposition (Figure 1). Potential 
mechanisms for environ mentally induced systemic auto­
immunity include interference with immune tolerance, 
activation of the immune system, induction of genetic 
alterations and dysregulation of epigenetic patterns.4,50 
The observation that fibroblasts taken from patients with 
SSc keep their altered behaviour for multiple passages 
when cultured outside the pathological context is one 
of the strongest indicators for the fundamental role of 
epigenetic regulation in SSc to date. Consistent with this 
theory, epi genetic modifications such as DNA methyla­
tion and histone modification (Box 2) have been shown 
to be important in determining gene activity in other 
autoimmune conditions, including SLE and RA.51,52 
Consequently, the study of epigenetic phenomena in SSc 
has flourished over the past few years, providing new 
insights into disease pathogenesis and novel potential 
therapeutic targets.
Herein, we provide a comprehensive overview of epi­
genetic markers and modifiers that have been shown to 
be altered in specific cell types or tissues taken directly 
from patients with SSc (Tables 1 and 2; Figure 2). We 
also outline how common epigenetic factors might be 
ap pealing targets for future therapeutic intervention 
for SSc.
DNA methylation
Altered DNA methylation in lymphocytes
Several studies have shown that SLE and RA are gen­
erally associated with global DNA hypomethylation 
that causes the overexpression of autoimmune­related 
genes.51 Similarly, CD4+ T cells from patients with SSc 
show a general reduction in the levels of DNA methy­
lation associated with a concurrent decreased expres­
sion of m ethylation­regulating genes, such as DNMT1, 
MBD3 and MBD4.53 The promoter of CD70 (also 
known as TNFSF7 or CD27L), which encodes the B­cell 
co­ stimulatory molecule CD70, is substan tially hypo­
methylated and probably contributes to the over expres­
sion of CD70 by CD4+ T cells of patients with SSc.54 In 
addition, CD4+ T cells from patients with SSc have high 
expression of CD40LG (which encodes CD40L; also 
known as CD154), which is located on the X chromosome 
Genetic factors
Mutations
SNPs
Chromosomal aberrations
Putative environmental factors
Silica dust
Vinyl chloride
Toxic oil
Solvents (e.g. trichloroethylene)
Drugs (e.g. bleomycin)
Infectious agents (e.g. Helicobacter pylori,
HCMV, EBV)
Epigenetic factors
DNA methylation
Histone modications
miRNAs
Aberrant gene and protein expression
Systemic sclerosis
Figure 1 | The pathogenesis of SSc is influenced by genetic, epigenetic and 
environmental factors.48,101 Several environmental factors have been proposed to 
contribute to the development of SSc; however, only exposure to silica has been 
proved to be associated with an increased SSc risk.50 Some environmental agents 
can induce genetic mutations or chromosomal rearrangements,4 but in most 
cases they probably induce epigenetic modifications to promote autoimmunity. 
By affecting the expression of individual genes on a genetic background that is 
already predisposed by the presence of SSc-susceptibility SNPs, aberrant 
epigenetic markers can promote the development of SSc. Abbreviations: EBV, 
Epstein–Barr virus; HCMV, human cytomegalovirus; SNP, single-nucleotide 
polymorphism; SSc, systemic sclerosis.
Box 2 | Epigenetic mechanisms
 ■ Epigenetics: heritable changes that influence gene expression without altering 
the DNA sequence; these changes include DNA methylation, post-translational 
modification of histones and miRNAs.
 ■ DNA methylation: describes the addition of a methyl group to CpG dinucleotides, 
mainly concentrated in CpG islands located within promoter regions. This 
addition promotes a more condensed DNA configuration, blocking accessibility 
to transcriptional activators and thereby inhibiting gene transcription; 
transcriptional activators can no longer bind because of tight chromatic 
configuration. Patterns of DNA methylation are established and maintained 
by DNA methyltransferases, whereas methyl-CpG-binding domain proteins 
associate with methyl-cytosine and recruit silencing complexes and histone 
deacetylases to consolidate the heterochromatic state (as in, maintain the 
tighter, closed DNA configuration of heterochromatin).
 ■ Histone modifications: includes acetylation, phosphorylation and methylation 
of specific histone residues that influence the accessibility of chromatin 
to transcription factors at gene promoters and enhancers. Histone 
acetylation, which promotes a more open chromatin structure, is catalysed 
by histone acetyltransferase enzymes. Histone deacetylases remove acetyl 
groups causing DNA to wrap more tightly around the nucleosome, thereby 
repressing gene expression. Histones can be also methylated by histone 
methyltransferases, or demethylated by histone demethylases. Histone H3 
trimethylation at lysine 4 (H3K4me3) is associated with active chromatin and 
gene expression. By contrast, methylation at histone H3 on lysine 9 (H3K9me) 
or histone H3 trimethylation at lysine 27 (H3K27me3) represses transcription 
by inducing a condensed heterochromatin status.
 ■ miRNAs: short, noncoding RNAs of 18–23 nucleotides that function as 
endogenous inhibitors of gene expression by binding the 3' untranslated region 
of target mRNAs, and thereby inhibiting their translation or promoting mRNA 
destabilization and degradation. miRNAs are expressed in a tissue-specific and 
cell type-specific manner, but can also stably circulate in biological fluids by 
associating with carrier proteins or being incorporated in microvescicles such 
as exosomes and apoptotic bodies.
Abbreviations: CpG, cytosine–guanine linear dinucleotide; miRNA, microRNA.
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and is thought to be important in SSc pathogenesis 
given that its blockade attenuates skin fibrosis and auto­
immunity in the tight­skin mouse model.55 Interestingly, 
CD40LG upregulation specifically occurred in female 
patients with SSc and correlated with hypomethylation 
of its promoter, suggesting that the altered methylation 
pattern of CD40LG—and possibly of other genes on the 
X chromosome—might contribute to the striking sus­
ceptibility of women to SSc.56 Supporting this hypothesis, 
the DNA methylation profile of peripheral blood mono­
nuclear cells from monozygotic twins discordant for SSc 
showed that only X chromosome sites were consistently 
either hypermethylated or hypomethylated.57 However, 
these observations fail to demonstrate the functional 
consequence of the altered DNA methylation pattern 
on the phenotype of peripheral leukocytes from patients 
with SSc. Another report indicated that increased DNA 
methylation of regulatory sequences in FOXP3 from 
CD4+ T cells from patients with SSc affected the expres­
sion of this key transcription factor, which is required for 
the generation of regulatory T cells. This study was the 
first demonstration of a direct link between changes in 
the DNA methylation pattern and the number of CD4+ 
regulatory T cells in SSc.58 Interestingly, FOXP3 hyper­
methylation has previously been suggested to be influ­
enced by X chromosomal inactivation patterns in SSc.4 
These findings might suggest an epigenetically mediated 
loss of immune homeostasis in SSc development.
Table 1 | Epigenetic alterations in SSc at the level of DNA methylation and histone marks
Epigenetic 
alteration
Finding in SSc Tissue Gene affected Gene product Impact on gene 
expression
References
DNA methylation
Pattern Hypomethylation  
and hypermethylation
PBMCs from 
monozygotic twins
X-chromosome genes X-chromosome-
derived proteins
Upregulation and 
downregulation
Selmi et al. (2012)57
Hypomethylation Female CD4+ T cells CD40LG CD40L Upregulation Lian et al. (2012)56
Hypomethylation CD4+ T cells CD70 CD70 Upregulation Jiang et al. (2012)54
Hypermethylation Fibroblasts, PBMCs, 
bleomycin-treated skin
DKK1 and SFRP1 DKK1 and 
SFRP1
Downregulation Dees et al. (2013)60
Hypermethylation Fibroblasts FLI1 FLI1 Downregulation Wang et al. (2006)59
Hypermethylation MVECs and skin BMPR2 BMPR2 Downregulation Wang et al. (2013)61
Enzyme 
affected
Decreased DNMT1, MBD3 
and MBD4 
CD4+ T cells Global 
hypomethylation
ND Upregulation Komura et al. 
(2008)55
Increased DNMT1, MBD1 
and MeCP2 
Fibroblasts Global 
hypermethylation
ND Downregulation Wang et al. (2006)59
Inhibitor* 5-aza-2'-deoxycytidine 
(DNMT)
Fibroblasts Global 
hypomethylation, 
FLI1, DKK1, SFRP1
FLI1, DKK1, 
SFRP1
Upregulation Wang et al. (2006)59 
Dees et al. (2013)60
Histone modification
Pattern H3 and H4 deacetylation Fibroblasts FLI1 FLI1 Downregulation Wang et al. (2006)59
H4 hyperacetylation and 
H3K9 hypomethylation
B cells ND ND Upregulation Wang et al. (2013)69
Increased H3K27me3 Fibroblasts ND ND Downregulation Kramer et al. (2013)68
Enzyme 
affected
Increased p300 (histone 
acetyltransferase)
Fibroblasts and skin Increased COL1A2 
acetylation
Collagen-α2(I) Upregulation Ghosh et al. (2013)64
Increased HDAC1  
and HDAC6 
Fibroblasts Global deacetylation ND Downregulation Wang et al. (2006)59
Decreased HDAC2  
and HDAC7
B cells Global histone H4 
hyperacetylation 
ND Upregulation Wang et al. (2013)69
Increased KDM3a  
(histone demethylase), 
decreased SUV39H2 
(histone methyltransferase)
B cells Global histone H3K9 
hypomethylation 
ND Upregulation Wang et al. (2013)69
Inhibitor* Trichostatin A (HDAC) Fibroblasts and 
bleomycin-treated skin
Global 
hyperacetylation
ND Upregulation Wang et al. (2006)59 
Huber et al. (2007)62 
Hemmatazad et al. 
(2009)63
3-deazaneplanocin A 
(histone methylation)
Fibroblasts and 
bleomycin-treated skin
Global inhibition of 
H3K27me3, FOSL2
FOSL2 Upregulation Kramer et al. (2013)68
*The effect of chemicals modulating DNA methylation and histone modifications on fibroblasts in the context of SSc are also summarized; the target is indicated in parentheses. Abbreviations: 
BMPR2, bone morphogenetic protein receptor 2; DKK1, Dickkopf-related protein 1; DNMT, DNA methyltransferase; FLI1, Friend leukemia integration 1 transcription factor; FOSL2, FOS-like 
antigen 2; HDAC, histone deacetylase; KDM3A, lysine-specific demethylase 3A (also known as JmjC domain-containing histone demethylation protein 2A); MBD, methyl-CpG-binding domain 
protein; me, methylation; MeCP2, methyl-CpG-binding protein 2; MVECs, microvascular endothelial cells; ND, not determined; PBMCs, peripheral blood mononuclear cells; SFRP1, secreted 
frizzled-related protein 1; SSc, systemic sclerosis; SUV39H2, suppressor of variegation3-9 homologue 2.
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Altered DNA methylation in other cell types
In contrast to CD4+ T cells, altered DNA methylation 
has been more robustly demonstrated in fibroblasts from 
patients with SSc. Skin biopsy samples from patients 
with SSc and derivative fibroblasts showed consider­
ably higher levels of the methylation­regulating genes 
DNMT1, MBD1 and MECP2 than samples from healthy 
controls, indicative of global DNA hyper methylation in 
fibroblasts from patients with SSc. Consistent with this 
finding, increased DNA methylation was observed in 
the promoter region of FLI1, which encodes an inhibi­
tor of collagen expression, and treatment with 5­aza­2'­ 
deoxycytidine (an inhibitor of DNA methyltransferases; 
DNMTs) decreased the level of collagen in fibroblasts 
from patients with SSc, indicating that epigenetic mec­
hanisms might mediate the fibrotic manifestations 
of SSc.59 Hypermethylation in these fibroblasts also 
affects Wnt signalling, one of the central profibrotic 
path ways in SSc, by silencing the expression of the Wnt 
antagonists DKK1 and SFRP1. Treatment with 5­aza­2'­ 
deoxycytidine restored the expression of both genes, 
thereby blocking activation of the Wnt pathway and 
reducing bleomycin­induced fibrosis.60
Microvascular endothelial cells from patients with SSc 
were reported to show extensive CpG hyper methylation 
of the promoter of the gene encoding bone morpho­
genetic protein receptor type­2 (BMPR2), which is 
important in the pathogenesis of familial pulmonary 
arterial hypertension.61 This abnormal methylation 
downregulated the expression of BMPR2 and rendered 
microvascular endothelial cells more vulnerable to 
apop tosis induced by serum starvation and oxidation 
injury, potentially contributing to the endothelial cell 
apoptosis that characterizes SSc lesional skin.
In summary, these studies demonstrate that the 
modulation of DNA methylation, potentially by using 
DNMT inhibitors that are already approved for clini­
cal use, might modulate the activity of cells involved in 
the pathogenesis in SSc, possibly ameliorating fibrosis 
in this condition.
Histone modifications
Histone acetylation in fibroblasts
The crucial role of histone acetylation in SSc patho­
genesis became evident from studies analysing the 
effect of the histone deacetylase (HDAC) inhibitor tri­
chostatin A (TSA) on gene expression in fibroblasts 
from patients with SSc. TSA promotes a state of histone 
hyperacetylation, which is associated with an increased 
rate of gene transcription that attenuates the expres­
sion of COL1A1 and FN1, which encode collagen I 
and fibronectin, respectively, in both normal and SSc 
skin fibroblasts.59,62 This process occurs under resting 
or stimu lated conditions, in response to transform­
ing growth factor (TGF)­β, IL­4 and platelet­derived 
growth factor (PDGF).62 TSA also prevented the dermal 
accumulation of extracellular matrix (ECM) in a mouse 
model of bleomycin­induced skin fibrosis.62 At least three 
Table 2 | miRNAs dysregulated in SSc
miRNA Expression  
in SSc
Tissue Validated 
target genes
Gene product Stimuli* Role in 
fibrosis
References
miR-7 Upregulated Fibroblasts, skin COL1A1, 
COL2A1
Collagen α-1(I), 
collagen α-1(II)
TSP2 Antifibrotic Kajihara et al. (2012)87
miR-21 Upregulated Fibroblasts, skin, 
bleomycin-treated skin
SMAD7 SMAD7 TGF-β Profibrotic Zhu et al. (2012)71
Zhu et al. (2013)74
miR-29a Downregulated Fibroblasts, skin, 
bleomycin-treated skin
COL1A1, 
COL3A1
Collagen α-1(I), 
collagen α-1(III)
TGF-β, 
PDGF-β, 
IL-4
Antifibrotic Zhu et al. (2012)71 
Maurer et al. (2010)78 
Bhattacharyya et al. (2013)79
miR-30b Downregulated Skin, bleomycin-treated 
skin, serum
PDGFRB PDGFR-β TGF-β Antifibrotic Tanaka et al. (2013)84
miR-92a Upregulated Fibroblasts, serum MMP1 MMP1 TGF-β Profibrotic Sing et al. (2012)86
miR-129-5p Downregulated Fibroblasts COL1A1 Collagen α-1(I) IL-17A Antifibrotic Nakashima et al. (2012)83
miR-142-3p Upregulated Serum ND ND ND ND Makino et al. (2012)90
miR-145, 
miR-125b, 
miR-206
Downregulated Skin ND ND ND ND Li et al. (2012)70 
Zhu et al. (2012)71
miR-150 Downregulated Fibroblasts, skin, 
serum
ITGB3 Integrin β3 ND Antifibrotic Honda et al. (2013)73
miR-196a Downregulated Fibroblasts, skin,  
hair shaft, skin of 
tight-skin mice
COL1A1, 
COL2A1
Collagen α-1(I), 
collagen α-1(II)
TGF-β Antifibrotic Honda et al. (2012)72 
Makino et al. (2013)81 
Wang et al. (2013)82
let-7a Downregulated Skin, serum COL1A1, 
COL2A1
Collagen α-1(I), 
collagen α-1(II)
TGF-β Antifibrotic Makino et al. (2013)80
let-7g Upregulated Skin ND ND ND ND Li et al. (2012)70
Not all evidence is reported at both the gene and protein level. *Stimuli demonstrated to be responsible for miRNA dysregulation in SSc or able to modulate miRNA expression in a similar 
manner to that occurring in SSc and therefore possibly responsible for their dysregulation. Abbreviations: miRNA, microRNA; MMP1, matrix metalloproteinase-1; ND, not determined; 
PDGF, platelet-derived growth factor; PDGFR-β, platelet-derived growth factor receptor β; SMAD7, mothers against decapentaplegic homolog 7; TGF-β, transforming growth factor β; TSP2, 
thrombospondin 2.
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mechanisms can explain the inhibitory effect of TSA on 
fibroblast activation. First, TSA can restore the expres­
sion of the negative regulator of collagen expression FLI1, 
which is usually repressed in SSc by promoter hypo­
acetylation and DNA methylation (as described above).59 
Furthermore, TSA reportedly inhibits the activation of 
the transcription factors SMAD3 and SMAD4 by TGF­β, 
thereby interfering with the signalling pathway involved 
in tissue fibrosis.62 In addition, the strong inhibition of 
HDAC7 expression by TSA in turn downregulates the 
expression of COL1A1 and COL3A1, both in resting cells 
and in those stimulated with TGF­β.63
These results suggest that HDAC inhibitors might 
be an effective treatment for skin fibrosis. How ever, 
given that HDACs are involved in crucial processes 
such as development and cell differentiation, treatment 
specificity should be carefully evaluated. In addition, 
as well as inhibiting the expression of collagen proteins 
in fibroblasts in SSc, TSA concurrently upregulated 
the expression of other pro fibrotic molecules, such as 
connective tissue growth factor and intercellular adhe­
sion mo lecule­1, that might contribute substantially to 
the development of skin fibrosis.63 Finally, the levels of 
expression of HDAC genes in SSc skin might also influ­
ence the effectiveness of HDAC inhibitors; however, 
reports from the literature are conflicting. Hemmatazad 
et al.63 reported similar levels of expression of all HDAC 
genes (HDAC1 to HDAC11) between fibroblast from 
patients with SSc and controls, whereas others59 showed 
increased levels of HDAC1 and HDAC6 protein in 
fibroblast s in the context of SSc.
In contrast to HDACs, the protein level of histone 
acetyltransferase p300 has been shown to be consist­
ently increased in fibroblasts and skin biopsy samples 
from patients with SSc in multiple studies compared 
with healthy samples.64,65 Interestingly, maximal stimu­
lation of collagen synthesis by TGF­β depends on the 
activity of p300,66 which facilitates the access of TGF­β­
activated SMAD2/3 to the COL1A2 promoter by increas­
ing its acetylation.64 Given that TGF­β itself can induce 
p300 expression via the activation of Egr1, a profibrotic 
transcription factor that is also upregulated in biopsy 
samples from patients with SSc,67 the overexpression of 
p300 is thought to promote an epigenetic feed­forward 
am plification of fibrosis in SSc in concert with TGF­β 
and Egr1.
Histone H3 Lys27 trimethylation in fibroblasts
Whereas DNMT and HDAC inhibitors have anti fibro­
tic effects, 3­deazaneplanocin A, a potent inhibitor 
of trimethylation of histone H3 on lysine 27, stimu­
lates fibroblasts to release collagen and exacerbates 
bl eomycin­induced and TGF­β­receptor­induced 
experimental fibrosis in vivo,68 indicating a clear role for 
this histone modification as a negative regulator of fibro­
sis. However, although the total levels of trimethylated 
histone H3 are increased in fibroblasts from patients with 
SSc as compared with those from healthy controls, they 
are not sufficient to block excessive collagen deposition 
by such fibroblasts.68
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Figure 2 | SSc pathophysiology involves the dysregulation of multiple cell types.  
This cell dysregulation results in aberrant immune activation, vascular damage, 
fibroblast activation, excessive collagen and ECM deposition and skin fibrosis. 
Genetic and epigenetic factors known to affect the activity of a | APCs, T cells,  
B cells and b | fibroblasts are indicated in the figure: genes known to influence SSc 
susceptibility are indicated next to the DNA; miRNAs and molecules upregulated or 
downregulated in SSc at the epigenetic level are shown respectively in grey boxes 
with a red border and orange boxes with a red border. The solid lines indicate that  
the inhibition is enforced because of miRNA upregulation; whereas dashed lines 
indicate that the inhibition is lost because of miRNA downregulation. Abbreviations: 
APC, antigen-presenting cell; BANK1, B-cell scaffold protein with ankyrin repeats; 
BLK, B-lymphocyte kinase; CD40L, CD40 ligand; DKK1, Dickkopf-related protein 1; 
ECM, extracellular matrix; FLI1, Friend leukemia integration 1 transcription factor; 
IRAK1, IL-1 receptor-associated kinase 1; IRF, interferon regulatory factor; LAP, 
latency-associated peptide; miR, microRNA; MMP1, metalloproteinase-1; NLRP1, 
nucleotide-binding oligomerization domain, leucine-rich repeat and pyrin domain-
containing protein 1; PDGF, platelet-derived growth factor; PDGFRβ, platelet-derived 
growth factor receptor β; SFRP1, secreted frizzled-related protein 1; SMAD, mothers 
against decapentaplegic homologue; STAT4, signal transducer and activator of 
transcription 4; TBX21, T-Box 21 transcription factor (T-bet); TCR, T-cell receptor; 
TGF-β, transforming growth factor β; TNIP1, TNFAIP3-interacting protein 1 protein 1; 
TNFSF4, TNF ligand superfamily member 4.
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Histone modification in B cells
The alteration of histone modifications in SSc is not 
confined to fibroblasts. Global hyperacetylation of his­
tone H4 and hypomethylation of H3 on lysine 9 have 
been detected in B cells from patients with SSc; these 
changes correlated with altered levels of the histone 
modi fication enzymes HDAC2 and SUV39H2 and clini­
cal parameters, such as skin thickness and disease activ­
ity.69 Even if these results are purely descriptive (as in, 
do not show functional analysis), they suggest that the 
abnormal histone modification pattern of autoimmune­
related genes might contribute to B­cell activation and 
the development of autoimmunity.
miRNAs
Expression profiling has revealed the presence of a dif­
ferent miRNA pattern in skin70,71 and fibroblasts cultured 
ex vivo72,73 from patients with SSc compared with healthy 
controls. Functional studies subsequently dem onstrated 
that differentially expressed miRNAs have a crucial role in 
SSc fibrosis by modulating multiple fibrosis­related genes 
such as those encoding collagens, metallopeptidase s and 
integrins (Table 2).
miR-21
A detailed study by Zhu et al.74 demonstrated that 
increased levels of miR­21 contribute to the upregulation 
of fibrosis­related genes (for example, ACTA2, COL1A1, 
COL1A2, and FN1) in fibroblasts from patients with SSc 
by negatively regulating SMAD7, an endogenous feedback 
inhibitor of TGF­β signalling, and therefore perpetuating 
the action of TGF­β. Consistent with these findings, the 
expression of miR­21 is also increased in other fibro tic 
conditions, such as post­ischaemic reperfusion, heart 
failure and idiopathic pulmonary fibrosis,75,76 and in 
b leomycin­induced skin fibrosis; by contrast, the chemi­
cal inhibition of fibrosis by bortezomib restored the levels 
of miR­21 and Smad7 in bleomycin­treated mice.74 The 
upregulation of miR­21 in the skin of patients with SSc is 
probably caused by exposure to TGF­β, which is known 
to induce the expression of this miRNA in vitro.74–76
miR-29a
The miR­29 family (miR­29a, miR­29b and miR­29c) is a 
class of antifibrotic miRNAs that oppose the profibrotic 
activity of miR­21. Decreased expression of miR­29 is 
associated with multiple fibrotic conditions, including 
cardiac, pulmonary and liver fibrosis,77 and three distinct 
studies have clearly demonstrated that miR­29 levels are 
also decreased both in skin tissues and fibroblasts from 
patients with SSc that are cultured ex vivo.71,78,79 The pro­
fibrotic stimuli TGF­β, PDGF or IL­4 inhibited miR­29a 
both in vitro and in vivo,78 suggesting that they are also 
responsible for its downregulation in the skin of patients 
with SSc. Given that miR­29 was shown to directly repress 
the expression of COL1A1, COL1A2 and COL3A1, low 
levels of this miRNA in patients with SSc are likely to 
lead to the uncontrolled accumulation of ECM pro teins, 
thereby contributing to a positive­ feedback loop that 
pr omotes fibrosis.78
Additional miRNAs
In addition to the well­established role of miR­21 and 
miR­29a in driving fibrosis in SSc, other miRNAs that 
are potentially involved in SSc pathogenesis include 
let­7a, miR­196a, miR­129­5p, miR­30b and miR­92a. 
Given that TGF­β can modulate the expression of 
these miRNAs in vitro and in vivo in a similar manner 
as observed in SSc­skin or fibroblasts,72,73 their dys­
regulation is probably the consequence of the excessive 
exposure of fibroblasts in patients with SSc to TGF­β. 
Although reports that link these miRNAs to SSc are 
sporadic, functional studies indicate that they might be 
actively involved in the ongoing fibrosis in SSc. Down­
regulation of let­7a contributes to the accumulation of 
type I collagen in fibroblasts in the context of SSc, and 
the intermittent overexpression of let­7a in the skin by 
intraperitoneal miRNA injection improved skin fibrosis 
induced by bleomycin in mice.80
In fibroblasts from healthy donors, miR­196a func­
tions to inhibit the production of type I collagen72 and its 
expression is under the control of the discoidin domain 
receptor 2 (DDR2).81 However, in fibroblasts from 
patients with SSc, the increased production of TGF­β 
directly inhibits the expression of both miR­196a and 
DDR2, thereby impairing the miR­196a­mediated nega­
tive feedback that controls type I collagen production 
and tissue fibrosis.81 Interestingly, the observation of 
decreased levels of miR­196a in the hair shafts of patients 
with SSc82 indicates that miR­196a might be considered 
as a noninvasive biomarker for SSc diagnosis.
Normally, IL­17A induces the expression of miR­ 
129­5p, which is responsible for the IL­17­mediated 
inhi bition of collagen expression at the post­ transcrip­
tional level, but in fibroblasts from patients with SSc, 
miR­129­5p is downregulated as a result of TGF­β 
inhibit ing the expression of IL17RA (which encodes 
the IL­17 receptor type A) and, consequently, impairing 
IL­17 signalling.83
Decreased expression of miR­30b maintains the 
TGF­β­mediated induction of the PDGF receptor and 
fibroblast proliferation.84,85 Moreover, the consequence 
of miR­92a overexpression might contribute to excessive 
collagen accumulation in fibroblasts from patients with 
SSc through the downregulation of MMP1.86
As well as a prominent role for TGF­β in regulating 
the expression of SSc­associated miRNAs, other factors 
can also influence the expression and, consequently, the 
activity of miRNAs in fibroblasts in SSc. Constitutive 
downregulation of miR­150, possibly through hyper­
methylation of its promoter, has been proposed to cause 
the upregulation of its direct target, β3­integrin, thus 
promoting the binding of latency associated peptide to 
the cell surface and the release of bioactive TGF­β.73 By 
contrast, the decreased intracellular levels of the pro­
fibrotic factor thrombospondin 2 that occur in fibro­
blasts in the context of SSc result in the upregulation of 
miR­7. Although miR­7 inhibits type I collagen produc­
tion, the potential negative­feedback circuit induced by 
the upregulation of miR­7 seems to be insufficient to 
normalize the excessive collagen synthesis in fibroblasts 
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from patients with SSc.87 These results require further 
investigation to reconcile this apparent contradiction.
Taken together, these data indicate that the patho­
genesis of SSc is influenced by aberrant gene expres­
sion arising from defective post­transcriptional control 
mediated by miRNAs. The modulation of miRNA 
expression by using miRNA inhibitors or mimics might, 
therefore, represent an attractive future opportunity for 
SSc treatment.
Circulating miRNAs
The detection of specific circulating miRNAs that corre­
late with SSc subset or disease severity could address the 
unmet need for reliable and accurate biomarkers of SSc. 
Although a comprehensive profile of circulating miRNAs 
is lacking, several studies have demonstrated that the 
levels of selected miRNAs are altered in the serum of 
patients with SSc.
Consistent with their expression in skin or fibroblasts 
in the context of SSc, the levels of miR­150, let­7a and 
miR­30a were, respectively, upregulated and down regu­
lated in the serum of patients with SSc versus healthy 
con trols, indicating that these miRNAs could be used 
as easily accessible biomarkers for SSc diagnosis.73,80,84 
Interest ingly, patients with SSc who have the lowest 
serum levels of miR­150 showed an increased frequency 
of pitting scars or ulcers and the presence of ATA, 
whereas miR­30a levels were inversely correlated with 
modified Rodnan skin scores;73,84 however, these correla­
tions seem more sporadic than systematically associated 
with disease severity or a specific subclass.
The serum concentrations of let­7g, miR­21, miR­29a, 
miR­125b, miR­145, miR­206 and miR­196a are similar 
in patients with SSc and healthy controls, despite dif­
ferences in the skin; some of them, however, correlate 
weakly with SSc clinical parameters.72,88,89 For example, 
patients with lower miR­196a serum levels had a higher 
modified Rodnan skin score and an increased preva­
lence of pitting scars compared with those with normal 
miR­196a levels.72
Serum levels of miR­92a and miR­142­3p were mark­
edly higher in patients with SSc than in healthy indi­
viduals or in patients with SLE, dermatomyositis or 
scleroderma spectrum disorders,86,90 indicating that 
these miRNAs might provide useful diagnostic markers 
for the differentiation of SSc from other autoimmune 
dis eases. Larger, and more detailed, studies will be 
required to better evaluate the potential of these miRNAs 
as diagnostic or prognostic biomarkers for SSc.
Conclusions
Despite extensive efforts, genetic research to date is 
not able to explain fully the development of SSc, nor 
has implementation of any of the findings from this 
research into clinical practice been achieved. The main 
gaps in the value of genetic research in SSc are in the 
field of clinical translation. A powerful genetic approach 
would be to investigate the predictive value of specific 
genetic markers for severe complications, such as pul­
monary hypertension and pulmonary fibrosis. Baseline 
measurements of these genetic markers could indicate 
the need to monitor the potential development of these 
complications more tightly in patients at risk, or even 
allow for preventive care. Only a few genetic studies are 
currently addressing this issue, using follow­up data. 
This approach would position this field of research 
more prominently in clinical decision­making and would 
greatly enhance its scientific value.
A difficult concept to overcome is that SSc is still 
regarded as a multifactorial disease, such that clusters 
of genetic variants are thought to contribute to genetic 
susceptibility as a whole. Logically, the next step would 
be to apply gene–gene interaction analysis to investigate 
whether certain combinations of variants contribute to 
the overall risk of genetic susceptibility. This approach 
has the potential to identify cumulative effects, which 
might, therefore, account for a more substantial part of 
SSc disease risk than current individual genetic markers. 
Hopefully, techniques that address the high computa­
tional burden that is pivotal to perform these analyses 
will evolve alongside this strategy.
Of interest is the high degree of overlap between 
genetic risk factors for SSc and those for other auto­
immune diseases,91 known as ‘shared autoimmunity’. 
This concept implies that additional factors might regu­
late the development of a distinct autoimmune disease on 
a similar genetic background. These factors are probably 
epigenetic modifications, environmental factors or rare 
genetic variants. Although likely to be involved in a rare 
disease like SSc, rare variants have not been investigated 
with a similar scrutiny to epigenetic modifications or 
environmental factors. The most powerful way to iden­
tify the role of such rare variants would be to perform 
genetic association studies in families with SSc, which are 
rare. New technologies, such as next­ generation whole­
exome or genome sequencing, should hopefully enable a 
more definitive answer as to what drives the pathogenesis 
of SSc at the genetic level, as should DNA methylation 
profiling. Investigating methy lation patterns, which indi­
cate genomic regions that contribute to the epigenetic 
inheritance involved in the pathogenesis of SSc, would 
be informative in a discordant monozygotic twin study, 
but also for comparing autoimmune diseases with similar 
genetic backgrounds.
Furthermore, analysis of the crosstalk between SNPs 
and epigenetic modifications might clarify how SSc­
susceptibility SNPs located in noncoding regions can 
influence gene expression to ultimately lead to SSc 
pathogenesis. Disease­associated SNPs are increasingly 
recognized to have regulatory functions linked to epi­
genetics, given that they are enriched on the promoters 
of coding genes and in regions characterized by multiple 
chromatin marks.92,93 Consistent with these findings, a 
decreased number of activating epigenomic marks in SSc­
linked susceptibility genes have been reported.94 Finally, 
the presence of SNPs can also influence DNA methyla­
tion patterns,95 transcription­factor binding to promoter 
regions,96 and the sequence of miRNAs and their recog­
nition elements,97,98 thereby potentially influencing gene 
and miRNA activity and leading to SSc development.
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Several reports have demonstrated the power of a 
multiple­data­layers integration approach in identify­
ing molecular signatures and networks that orchestrate 
both physiological and pathological processes, such as 
the immune response and cancer.99,100 It is hoped that a 
similar systems­biology approach to further investigate 
the interplay between genetic, epigenetic and environ­
mental factors will help to unravel the complex molecu­
lar circuitry that orchestrates SSc pathogenesis, ultimately 
leading to the generation of effective treatments for this 
chronic inflammatory condition.
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